Skip to main content

Emerging treatments for rheumatoid arthritis: Update

Publication ,  Journal Article
Savage, C; St. Clair, EW; Sundy, JS
Published in: Consultant
August 1, 2005

Early treatment with disease-modifying anti-rheumatic drugs (DMARDs)-alone or in combination-can prevent joint damage and minimize disability. Until recently, the DMARDs used predominantly in patients with rheumatoid arthritis had been methotrexate, sulfasalazine, and hydoxychloroquine. Older DMARDs such as gold, D-penicillamine, and azathioprine have fallen out of favor because of their long-term toxicities or modest benefit. Six newer DMARDs-leflunomide, etanercept, infliximab, adalimumab, rituximab, and anakinra-have greatly expanded the current treatment options.

Duke Scholars

Published In

Consultant

ISSN

0010-7069

Publication Date

August 1, 2005

Volume

45

Issue

9

Start / End Page

984 / 995

Related Subject Headings

  • General & Internal Medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Savage, C., St. Clair, E. W., & Sundy, J. S. (2005). Emerging treatments for rheumatoid arthritis: Update. Consultant, 45(9), 984–995.
Savage, C., E. W. St. Clair, and J. S. Sundy. “Emerging treatments for rheumatoid arthritis: Update.” Consultant 45, no. 9 (August 1, 2005): 984–95.
Savage C, St. Clair EW, Sundy JS. Emerging treatments for rheumatoid arthritis: Update. Consultant. 2005 Aug 1;45(9):984–95.
Savage, C., et al. “Emerging treatments for rheumatoid arthritis: Update.” Consultant, vol. 45, no. 9, Aug. 2005, pp. 984–95.
Savage C, St. Clair EW, Sundy JS. Emerging treatments for rheumatoid arthritis: Update. Consultant. 2005 Aug 1;45(9):984–995.

Published In

Consultant

ISSN

0010-7069

Publication Date

August 1, 2005

Volume

45

Issue

9

Start / End Page

984 / 995

Related Subject Headings

  • General & Internal Medicine